Beta-Thalassaemia intermedia und minor (Kinder- und Jugendmedizin)
Pharmakologische Einleitung der fetalen Hämoglobinsynthese
Hydroxyharnstoff (Hydroxycarbamid)-Therapie
Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (öffnet neues Fenster)
Quelle: Hemoglobin 2014;38(1):44-8.
Hydroxyurea in thalassemia intermedia--a promising therapy. (öffnet neues Fenster)
Quelle: Ann Hematol 2005;84(7):441-6.
Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (öffnet neues Fenster)
Quelle: J Clin Pathol 2010;63(2):147-50.
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (öffnet neues Fenster)
Quelle: Eur J Haematol 2009;82(3):213-8.
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. (öffnet neues Fenster)
Quelle: J Pediatr Hematol Oncol 2005;27(7):380-5.
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (öffnet neues Fenster)
Quelle: Eur J Haematol 2010;84(1):52-8.
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. (öffnet neues Fenster)
Quelle: Pediatr Hematol Oncol 2003;20(6):429-34.
Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (öffnet neues Fenster)
Quelle: Ann N Y Acad Sci 2005;1054:250-6.
Rekombinantes Erythropoetin (allein oder in Kombination mit anderen Wirkstoffen)
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (öffnet neues Fenster)
Quelle: Acta Haematol 2004;111(4):189-95.
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. (öffnet neues Fenster)
Quelle: Eur J Haematol 2013;91(6):522-33.
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (öffnet neues Fenster)
Quelle: Pediatr Ann 2008;37(5):339-46.
Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. (öffnet neues Fenster)
Quelle: Br J Haematol 1995;90(2):341-5.
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (öffnet neues Fenster)
Quelle: Br J Haematol 2011;154(2):281-4.
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (öffnet neues Fenster)
Quelle: Blood Rev 2012;26 Suppl 1:S35-9.
Andere Substanzen
Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. (öffnet neues Fenster)
Quelle: Evid Based Complement Alternat Med 2009;6(2):141-51.
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. (öffnet neues Fenster)
Quelle: Br J Haematol 2013;161(4):587-93.
Butyric acid: what is the future for this old substance? (öffnet neues Fenster)
Quelle: Swiss Med Wkly 2012;142:w13596.